GRAIL, Inc. (GRAL)
| Market Cap | 2.03B +75.2% |
| Revenue (ttm) | 147.17M +17.2% |
| Net Income | -408.35M |
| EPS | -11.11 |
| Shares Out | 40.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,475,811 |
| Open | 49.66 |
| Previous Close | 101.53 |
| Day's Range | 48.00 - 56.75 |
| 52-Week Range | 20.44 - 118.84 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 100.50 (+100.16%) |
| Earnings Date | Feb 19, 2026 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for GRAL stock is "Strong Buy." The 12-month stock price target is $100.5, which is an increase of 100.16% from the latest price.
News
This once-hot cancer-detection company's stock got cut in half after a failed trial
Grail's stock was the Nasdaq's biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.
Grail shares plunge after major cancer screening trial misses main goal
Grail shares plunged nearly 50% in premarket trading on Friday after its three-year cancer screening trial failed to meet its main goal, dealing a major blow to the blood test maker.
Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.
The biotech company said its multi-cancer screening test Galleri did not lead to a “statistically significant reduction” in stage 3 and 4 cancer in a U.K. trial.
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO--(BUSINESS WIRE)---- $GRAL #Grail--Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Grail, Inc. (NASDAQ: GRAL). The investigation focuses on Grail's executive...
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 Million Completed Galleri PMA Submission to FDA Shared Topline Results from the NHS-Galleri Tr...
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time GRAIL Announces U.S. Sales Force Expansion Based on Stro...
GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fina...
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), ...
A Study on Aging Unlocks Holy Grail of Sports Performance
SAN FRANCISCO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Surprisingly, a study of older adults is getting a lot of buzz among peak performance experts in the world of sports. The recent INHANCE neuroimaging s...
GRAIL Inc. - Illumina's Divested Holy Grail
GRAIL (GRAL) offers MCED screening tests that offer employers economic value and employee health clarity. Divestiture of GRAIL by Illumina offers investors $8B valuation foundation. TAM valuation impl...
GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. , Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equ...
GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference
MENLO PARK, Calif. , Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold
Grail (GRAL) reported Q3 revenues of $36.2m, up 26% YoY, but continues to post significant losses and faces commercial challenges. Galleri test's PATHFINDER 2 study showed promising early cancer detec...
GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript
GRAIL, Inc. ( GRAL) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Robert Ragusa - CEO & Director Joshua Ofman - President Harpal Kumar - Chief Scientific Officer & Presiden...
GRAIL Reports Third Quarter 2025 Financial Results
Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position o...
GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference
MENLO PARK, Calif. , Nov. 4, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...
Top Biotech Stocks Riding The Rally
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock pric...
GRAIL to Announce Third Quarter 2025 Financial Results
Analyst Day 2025 Webcast to Begin at 11:00 a.m. ET on November 13 th MENLO PARK, Calif.
GRAIL: Buy Τhe Test That Could Redefine Cancer Screening
GRAIL moves from scientific vision to proven clinical reality, as PATHFINDER 2 confirms that multi-cancer early detection works effectively at scale. Physician and patient adoption is accelerating, su...
Odds of these speculative stocks making you money seems very slim, says Jim Cramer
CNBC's Jim Cramer discusses the day's market action and his take on speculative stocks.
GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript
GRAIL, Inc. (NASDAQ:GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection October 20, 2025 8:00 AM EDT Company Participants Robert Ragusa - CEO & Director Jo...